The first day of the collection: Olympic Weil is less than 1 yuan per film, 28 competition for one variety

On July 12, the seventh batch of drugs nationwide was purchased in Nanjing, Jiangsu, and the industry had revealed some results.

There are 61 drugs and 125 rules for this collection. Including chronic diseases such as hypertension, diabetes, anti -infection, digestive tract diseases, and major diseases such as lung cancer, liver cancer, kidney cancer, and bowel cancer. Different from the past few episodes, this collection will be held in two days. The bidding of the 1st to 30th varieties from July 12th, 31 to 61 varieties on July 13.

The results of the influenza treatment drug Osdowei were the first to be reported on the afternoon of July 12: more than 10 companies bids, and the winning bidding companies include Dongguang, Huahai Pharmaceutical, Coron Pharmaceutical, Stone Pharmaceutical Ouyi, Qilu Pharmaceutical and so on. The price of this variety is 6.45 yuan per piece, but the minimum quotation is only 0.99 yuan.

Olyvas, who had been 15 to 20 yuan each before, now settled to less than 1 yuan. People in the industry lamented: Another "magic medicine" fell. According to Mine.com data, Osdim Weir, who in 2019, set a sales achievement of 6 billion yuan.

Olympic Wei is definitely not an orphan. Many pharmaceutical companies have brought the greatest sincerity to maintain the existing hospital market. Analysts pointed out that this collection can save about 65 billion yuan for the medical insurance fund.

The price competition is fierce, with more than 10 varieties competition

"In the seventh batch of collection, the most intense competition may be Omeprazole injection." Jin Chunlin, director of the Shanghai Health and Healthy Development Research Center, told the media.

According to the collection document, the highest valid declaration price of 20 mg omeprazole is 8.2353 yuan. In the industry judgment: 27 reviews companies plus the original Astraikon, Omeprazole injection may have 28 competitions, but only 10 of them can be selected at most.

Industry insiders revealed that according to the on -site quotation, Harbin Sanlian, North China Pharmaceutical, Hang Seng Pharmaceutical, Fu'an Pharmaceutical, Coron Pharmaceutical, Bosen Biological, Hainan All -Star Pharmaceutical, Renfu Pharmaceutical, Cyron Pharmaceutical and Luo Xin Pharmaceutical 10 Family companies win the bid. Stone Medicine Ouyi, Kang Enbei, Yipinhong, Olympic Kang and other companies were selected.

In addition, in the auction of sulfuricate inhalation in inhalation in inhalation, Astraco has reported a price that is significantly beyond the competitors several times. In the end Ryte Pharmaceutical won the bid.

The commonly used pills of hypertension and angina pectoris are nodopine, and Bayer competes with 11 imitation companies. In 2021, the terminal sales data of China's public medical institutions showed that the annual sales of nonetopizen horizontal controlled dosage forms exceeded 6.6 billion yuan, and the market share of the original research manufacturers Bayer exceeded 70%. For this variety, 10 companies such as Bayer, Cube Pharmaceutical, Yiheng Pharmaceutical, and Baiyang Pharmaceuticals are qualified for winning the bid. According to industry insiders, Hefei Cube Pharmaceutical is one of the proposed bid companies.

National Pharmaceutical Concentrated Procurement Report Information Disclosure Conference site

More and more evaluation varieties have made the competition of national collection increasingly fierce. The Jianzhi Bureau sorted out and found that there were more than 14 varieties of competition in this round of more than 10 companies.

This round of collecting rules has changed, and a provincial double supply guarantee model is introduced

Since the start of the 4+7 pilot reform, the National Pharmaceutical Collection has been carried out in five rounds and six batches. The first six batches of national collection saves medical expenses exceeding 260 billion yuan. The large market size and sufficient competition have always been the focus of collection, and the seventh batch of national optics also continues the trend of large varieties.

The Jianzhi Bureau was informed that the seventh batch of collection adhered to the basic principles of "linked and priced, recruiting one" and the working mechanism of "national organization, alliance procurement, and platform operation", and made further adjustments and optimizations, strengthen supply guarantee, strengthen supply guarantee Essence

Different from the past, the seventh batch of national collection has undergone certain changes in rules.

The national collection is in exchange for the actual clinical amount of medical institutions in exchange for lower prices of pharmaceutical companies. The antibiotic variety is 10%lower than the purchase of ordinary drugs, which reflects the continuous improvement of national collection of changes in the market and disease spectrum.

As the number of enterprises selected in the collection varieties continues to increase, supply guarantee is an important prerequisite. From the current situation, it can be found that the larger the size of the enterprise, the more they will cherish their reputation, the quality of the drug will be more and more guaranteed, and there will be no big deviation in supply guarantee.

The national collection has added new rules for the preparation of regions and alternative enterprises, that is, a province's double supply guarantee supply model.

This model is the main supply and enterprises at the same time. When the main supply enterprise cannot be supplied in a timely manner or the qualifications of the selection, it can be switched to the public enterprise in time to ensure stable clinical use.

In accordance with national deployment, we must promote the normalization, institutionalization, and acceleration expansion of concentrated procurement, and continue to reduce the price of medical prices to benefit patients. Promoted by collecting policies, the competition in the Chinese pharmaceutical market has become increasingly fierce.

National Pharmaceutical Concentrated Procurement Report Information Disclosure Conference site

The industry generally believes that the national collection is nothing more than the two goals. One is to promote the high -quality development of domestic drugs; the other is to achieve price reductions and benefit more patients.

Note: The above information is summarized by the Jianzhi Bureau. In the end, the actual quotation and the medium price are based on the official disclosure data of the State Medical Insurance Bureau.

Writing | Lei Gong

Edit ｜ Jiang Yun Jia Ting

Operation | Twenty -thirty

### Innovative Pharmaceutical Company#

- END -